A randomised, double blind, placebo-controlled clinical trial to compare the progression of cognitive impairment in dementia patients continuing to take, or discontinued from, treatment with neuroleptics
Completed
- Conditions
- ervous System Diseases: DementiaNervous System DiseasesDementia
- Registration Number
- ISRCTN33368770
- Lead Sponsor
- Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 220
Inclusion Criteria
220 patients who will be living in nursing homes, at home with a carer, or in sheltered accommodation who fulfil the NINCDS/ADRDA for probable or possible Alzheimer's Disease and who have been taking neuroleptic medication for a minimum of three months
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cognitive decline in dementia patients discontinuing neuroleptic treatment?
How do antipsychotics compare to standard-of-care treatments in managing dementia-related behavioral symptoms?
Are there specific biomarkers that predict response to neuroleptic therapy in Alzheimer's or vascular dementia subtypes?
What are the long-term adverse event profiles of typical and atypical neuroleptics in elderly dementia populations?
How do dopamine receptor antagonists interact with cholinesterase inhibitors in dementia treatment regimens?